About: The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery—a Scottish Ophthalmological Surveillance Unit study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery—a Scottish Ophthalmological Surveillance Unit study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery—a Scottish Ophthalmological Surveillance Unit study
Creator	Erikitola, Ore-Oluwa Foot, • Lockington, • Siempis, •
Source	Medline; PMC
abstract	PURPOSE: Post-operative cystoid macular oedema (CMO) can cause deterioration of vision following routine cataract surgery. The incidence of persistent CMO (pCMO; defined as CMO present after 3 months) following uncomplicated surgery is uncertain. We wished to identify the incidence, management and visual outcomes of such patients. METHODS: A Scottish Ophthalmological Surveillance Unit (SOSU) questionnaire was sent monthly to every ophthalmic specialist in Scotland over an 18-month period from 1st January 2018 asking them to report all new patients with pCMO confirmed on OCT scanning following uncomplicated cataract surgery. A follow-up questionnaire was sent 9 months after initial presentation. RESULTS: Fourteen cases of pCMO were reported, giving an incidence of 2.2 cases of pCMO per 10,000 uncomplicated cataract surgeries. Mean age was 74.9 years (SD 10.2; range 44–86) with a male preponderance (72.7%). Two patients developed pCMO in each eye. Six cases (46.2%) had hypertension and one had diabetes. Three eyes required intracameral adjuncts (two iris hooks, one intracameral phenylephrine). Postoperative visual acuity (VA) at 3 months was logMAR 0.48 (0.2–0.8). Average mean central retinal thickness (CRT) at 3 months was 497microns (270–788). The most common initial treatment comprised topical steroids and topical NSAIDs (61.5%). Other management strategies included systemic steroids, intravitreal steroids and oral acetazolamide. At 1-year post-op, mean VA was logMAR 0.18 (0.1–0.3) with average mean CRT of 327microns (245–488). CONCLUSIONS: We identified a low incidence of pCMO following uncomplicated cataract surgery in Scotland (0.02%), with inconsistent and variable management regimes. A nationally agreed treatment protocol is required.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1038/s41433-020-0908-y
bibo:pmid	32376978
has license	no-cc
sha1sum (hex)	e7af1cbf0b47884a5092a54df53cd96d9653da80
schema:url	https://doi.org/10.1038/s41433-020-0908-y
resource representing a document's title	The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery—a Scottish Ophthalmological Surveillance Unit study
has PubMed Central identifier	PMC7202460
has PubMed identifier	32376978
schema:publication	Eye (Lond)
resource representing a document's body	covid:e7af1cbf0b47884a5092a54df53cd96d9653da80#body_text
is schema:about of	named entity 'surgery' named entity 'surgery' named entity 'cases' named entity 'systemic' named entity 'initial' named entity 'Surveillance' named entity 'incidence' named entity 'Ophthalmological' named entity 'PRESENT' named entity 'FOURTEEN' named entity 'FOLLOW-UP' named entity 'SYSTEMIC' named entity '0.48' named entity 'CONFIRMED' named entity 'INTRAVITREAL' named entity 'STEROIDS' named entity 'ASKING' named entity 'YEARS' named entity 'CMO' named entity 'wished' named entity 'developed' named entity 'hooks' named entity 'Results' named entity 'ophthalmic' named entity 'oral' named entity 'nationally' named entity 'cataract' named entity 'diabetes' named entity 'surgery' named entity 'identify' named entity 'steroids' named entity 'Scotland' named entity 'incidence' named entity 'Scotland' named entity 'ophthalmic specialist' named entity 'cataract surgeries' named entity 'steroids' named entity 'cataract surgery' named entity 'phenylephrine' named entity 'cataract surgery' named entity 'steroids' named entity 'intravitreal' named entity 'Two' named entity 'eye' named entity 'Scotland' named entity '20/50' named entity 'post-operative' named entity 'cataract surgery' named entity 'cataract surgery' named entity 'Cataract surgery' named entity 'local anaesthetic' named entity 'iris' named entity 'flurbiprofen' named entity 'topical steroid' named entity 'steroid injection' named entity 'prostaglandin analogues' named entity 'NSAIDs' named entity '2.2' named entity 'inflammatory mediators' named entity 'relative risk' named entity 'subconjunctival' named entity 'subconjunctival' named entity 'inflammation' named entity 'bromfenac' named entity 'pseudophakic' named entity 'OCT' named entity 'post-operative' named entity 'cataract surgery' named entity 'ophthalmologists' named entity 'dexamethasone' named entity 'cataract surgery' named entity 'diabetes' named entity 'NSAID' named entity 'diabetes mellitus' named entity 'modern cataract surgery' named entity 'phenylephrine' named entity 'bimatoprost' named entity 'Inflammation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software